The Readout Loud
STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
Mentioned books
Dec 20, 2018 • 27min
Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta
What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?
Dec 13, 2018 • 23min
Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests
Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?
Dec 6, 2018 • 23min
Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history
Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?
Nov 29, 2018 • 24min
Episode 38: Your guide to the #CRISPRbabies controversy
What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?
Nov 15, 2018 • 26min
Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts
Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?
Nov 8, 2018 • 23min
Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug
Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?
Nov 1, 2018 • 26min
Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence
Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does "folie à deux" mean?
Oct 25, 2018 • 22min
Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma
Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really?
Oct 18, 2018 • 25min
Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy
Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?
Oct 11, 2018 • 23min
Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn
Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?
